ABSTRACT
Shuwen Yu and Benjie Wang have served as speakers for Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Qiong Wu, Chao Pan, Xiangqing Yu, and Yuhui Liu are the employees of Jiangsu Hansoh Pharmaceutical Group Co., Ltd, the sponsor of the study, at the time of this study. The remaining authors declare no conflict of interest.Ibrexafungerp (code name in China: HS-10366) is a first-in-class and orally active triterpenoid antifungal agent with broad antifungal activity against 